AKTS · ISSUER CIK 2035832
Aktis Oncology, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 1 Aktis Oncology, Inc. insiders reported $0.00 of open-market purchases and $259K of sales on SEC Form 4.
↗1 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 1 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$259KInsider selling
−$259KNet open-market
Sep 24, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 202616:05 | Sep 23, 2026 | AKTS | Chief Medical Officer | S · Sell10b5-1 | $20.69 | −12,500 | 0 | -100% | −$259K | ||
| Sep 24, 202616:05 | Sep 23, 2026 | AKTS | Chief Medical Officer | M · Exercise10b5-1 | $4.95 | +12,500 | 12,500 | New | $62K |